Dario Giugliano
Overview
Explore the profile of Dario Giugliano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
256
Citations
9957
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Giugliano D, Longo M, Caruso P, Gicchino M, Scappaticcio L, Bellastella G, et al.
Diabetes Obes Metab
. 2025 Feb;
PMID: 39972376
No abstract available.
2.
Giugliano D, De Nicola L, Maiorino M, Esposito K
J Endocrinol Invest
. 2024 Nov;
48(2):295-298.
PMID: 39495477
No abstract available.
3.
Giugliano D, Esposito K, De Nicola L
J Nephrol
. 2024 Oct;
37(8):2347-2350.
PMID: 39356417
Acute kidney disease (AKD) is defined as subacute damage and/or loss of kidney function occurring 7 to 90 days after acute kidney injury (AKI), and bearing a high risk of...
4.
Giugliano D, Esposito K, De Nicola L
Diabetes Obes Metab
. 2024 Sep;
26(11):4813-4815.
PMID: 39219442
No abstract available.
5.
Caruso P, Maiorino M, Longo M, Porcellini C, Matrone R, Selvaggio L, et al.
JAMA Netw Open
. 2024 Mar;
7(3):e241545.
PMID: 38470420
Importance: Peripheral artery disease (PAD) in diabetes may lead to diabetic foot ulcer and lower-extremities amputation. Glucagon-like peptide 1 receptor agonists have proven cardiovascular benefits in trials of people with...
6.
Longo M, Caruso P, Scappaticcio L, Maiorino M, Bellastella G, Capuano A, et al.
Diabetes Obes Metab
. 2024 Jan;
26(4):1492-1501.
PMID: 38234208
Aim: To assess and compare the metabolic and vascular effectiveness of sodium-glucose cotransporter 2 inhibitors (SGLT-2i) and dipeptidyl peptidase-4 inhibitors (DPP-4i) in the clinical practice of patients with type 2...
7.
Giugliano D, Longo M, Scappaticcio L, Caruso P, Gicchino M, Petrizzo M, et al.
Endocrine
. 2023 Oct;
83(2):399-404.
PMID: 37787888
Purpose: To assess the magnitude and durability of the metabolic benefits by simplification of complex insulin treatments in patients with type 2 diabetes inadequately controlled by a full basal-bolus insulin...
8.
Caruso P, Maiorino M, Bellastella G, Esposito K, Giugliano D
Diabetes Metab Res Rev
. 2023 Feb;
39(7):e3627.
PMID: 36812501
No abstract available.
9.
Trabucco Aurilio M, Maiorino M, Mennini F, Scappaticcio L, Longo M, Nardone C, et al.
BMJ Open
. 2022 May;
12(5):e057825.
PMID: 35613811
Objectives: The aim of this study is to estimate the average number of claims for social security benefits from workers with diabetes-related disability. Design: Nationwide retrospective cohort study. Setting: The...
10.
Giugliano D, Longo M, Signoriello S, Maiorino M, Solerte B, Chiodini P, et al.
Cardiovasc Diabetol
. 2022 Mar;
21(1):42.
PMID: 35296336
Background: Glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium glucose co-transporter-2 (SGLT-2) inhibitors reduce cardiorenal outcomes. We performed a network meta-analysis to compare the effect on cardiorenal outcomes among GLP-1 RAs,...